Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder

被引:33
|
作者
Malhi, Gin S. [1 ,2 ]
Bargh, Danielle M. [1 ,2 ]
McIntyre, Roger [3 ,4 ,5 ,6 ]
Gitlin, Michael [7 ]
Frye, Mark A. [8 ,9 ]
Bauer, Michael [10 ]
Berk, Michael [11 ,12 ,13 ,14 ,15 ,16 ]
机构
[1] Univ Sydney, CADE Clin, Dept Psychiat, Royal N Shore Hosp, Sydney, NSW 2006, Australia
[2] Royal N Shore Hosp, Discipline Psychiat, Sydney Med Sch, Sydney, NSW, Australia
[3] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[4] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[5] Univ Hlth Network, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada
[6] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada
[7] Univ Calif Los Angeles, Dept Psychiat, David Geffen Sch Med, Los Angeles, CA USA
[8] Mayo Mood Clin, Dept Psychiat, Rochester, MN USA
[9] Mayo Coll Med, Res Program, Rochester, MN USA
[10] Tech Univ Dresden, Dept Psychiat & Psychotherapy, Carl Gustav Carus Univ Hosp, D-01062 Dresden, Germany
[11] Deakin Univ, Sch Med, Geelong, Vic 3217, Australia
[12] Univ Melbourne, Orygen Youth Hlth Res Ctr, Ctr Youth Mental Hlth, Parkville, Vic 3052, Australia
[13] Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia
[14] Barwon Hlth, Geelong, Vic, Australia
[15] Swanston Ctr, Geelong Clin, Geelong, Vic, Australia
[16] Mental Hlth Res Inst Victoria, Parkville, Vic, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
acute treatment; bipolar disorder; evidence-based review; guidelines; maintenance treatment; treatment; PLACEBO-CONTROLLED TRIAL; LONG-TERM TREATMENT; OLANZAPINE-FLUOXETINE COMBINATION; LITHIUM MAINTENANCE TREATMENT; TREATMENTS CANMAT GUIDELINES; CONTROLLED 18-MONTH TRIAL; WEEKLY SYMPTOMATIC STATUS; DEPRESSIVE MIXED-STATE; OPEN-LABEL EXTENSION; DOUBLE-BLIND;
D O I
10.1111/j.1399-5618.2012.00989.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To provide practical and clinically meaningful treatment recommendations that amalgamate clinical experience and research findings for each phase of bipolar disorder. Methods: A comprehensive search of the literature was undertaken using electronic database search engines (Medline, PubMed, Cochrane reviews) using key words (e.g., bipolar depression, mania, treatment). All relevant randomised controlled trials were examined, along with review papers, meta-analyses, and book chapters known to the authors. In addition, the recommendations from accompanying papers in this supplement have been distilled and captured in the form of summary boxes. The findings, in conjunction with the clinical experience of international researchers and clinicians who are practiced in treating mood disorders, formed the basis of the treatment recommendations within this paper. Results: Balancing clinical experience with evidence informed and lead to the development of practical clinical recommendations that emphasise the importance of safety and tolerability alongside efficacy in the clinical management of bipolar disorder. Conclusions: The current paper summarises the treatment recommendations relating to each phase of bipolar disorder while providing additional, evidence-based, practical insights. Medication-related side effects and monitoring strategies highlight the importance of safety and tolerability considerations, which, along with efficacy information, should be given equal merit.
引用
收藏
页码:1 / 21
页数:21
相关论文
共 50 条
  • [1] Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy
    Citrome, Leslie
    [J]. ADVANCES IN THERAPY, 2013, 30 (02) : 102 - 113
  • [2] Aripiprazole in bipolar disorder: clinical strategies to maximize efficacy and tolerability
    Andrea Fagiolini
    [J]. Annals of General Psychiatry, 9 (Suppl 1)
  • [3] Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy
    Leslie Citrome
    [J]. Advances in Therapy, 2013, 30 : 102 - 113
  • [4] Individualizing Treatment for Patients With Bipolar Disorder: Optimizing Efficacy, Safety, and Tolerability
    Correll, Christoph U.
    [J]. ANNALS OF CLINICAL PSYCHIATRY, 2011, : 49 - 81
  • [5] Safety and Tolerability of Lamotrigine for Bipolar Disorder
    Charles L. Bowden
    Gregory M. Asnis
    Lawrence D. Ginsberg
    Beth Bentley
    Robert Leadbetter
    Robin White
    [J]. Drug Safety, 2004, 27 : 173 - 184
  • [6] Safety and tolerability of lamotrigine for bipolar disorder
    Bowden, CL
    Asnis, GM
    Ginsberg, LD
    Bentley, B
    Leadbetter, R
    White, R
    [J]. DRUG SAFETY, 2004, 27 (03) : 173 - 184
  • [7] A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder
    Zajecka, JM
    Weisler, R
    Sachs, G
    Swann, AC
    Wozniak, P
    Sommerville, KW
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (12) : 1148 - 1155
  • [8] Safety and tolerability of anticonvulsant medication in bipolar disorder
    Pichler, Eva Maria
    Hattwich, Georg
    Grunze, Heinz
    Muehlbacher, Moritz
    [J]. EXPERT OPINION ON DRUG SAFETY, 2015, 14 (11) : 1703 - 1724
  • [9] Safety and tolerability of lamotrigine in bipolar I disorder
    Vieta, E
    Young, A
    Berk, M
    Asnis, G
    Calabrese, J
    Sachs, G
    Bowden, C
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S265 - S265
  • [10] Safety and tolerability of lamotrigine in bipolar I disorder
    Vieta, E
    Young, A
    Berk, M
    Asnis, G
    Sachs, G
    Bowden, C
    Calabrese, J
    [J]. BIPOLAR DISORDERS, 2004, 6 : 33 - 34